1.

Record Nr.

UNINA9910959758103321

Titolo

Saving lives, buying time : economics of malaria drugs in an age of resistance / / Committee on the Economics of Antimalarial Drugs, Board on Global Health ; Kenneth J. Arrow, Claire Panosian, and Hellen Gelband, editors

Pubbl/distr/stampa

Washington, D.C., : National Academies Press, c2004

ISBN

9786610176120

9780309165938

0309165938

9781280176128

1280176121

9780309532334

0309532337

Edizione

[1st ed.]

Descrizione fisica

1 online resource (384 p.)

Altri autori (Persone)

ArrowKenneth Joseph <1921->

PanosianClaire

GelbandHellen

Disciplina

616.9/362061

Soggetti

Antimalarials - Economic aspects

Pharmaceutical policy

Drug resistance in microorganisms

Malaria - drug therapy

Antimalarials - therapeutic use

Drug Costs

Drug Resistance

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Bibliographic Level Mode of Issuance: Monograph

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

FrontMatter -- Reviewers -- Preface -- Acknowledgments -- Contents -- Executive Summary -- PART 1 A Response to the Current Crisis -- 1 Malaria Today -- 2 The Cost and Cost-Effectiveness of Antimalarial Drugs -- 3 The Case for a Global Subsidy of Antimalarial Drugs -- 4 An International System for Procuring Antimalarial Drugs -- PART 2 Malaria Basics -- 5 A Brief History of Malaria -- 6 The Parasite, the



Mosquito, and the Disease -- 7 The Human and Economic Burden of Malaria -- 8 Malaria Control -- 9 Antimalarial Drugs and Drug Resistance -- PART 3 Advancing Toward Better Malaria Control -- 10 Research and Development for New Antimalarial Drugs -- 11 Maximizing the Effective Use of Antimalarial Drugs -- Acronyms and Abbreviations -- Glossary -- Index.

Sommario/riassunto

For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africa "currently just over one million per year "are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called  oeartemisinins are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.